Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from ImmuPharma ( (GB:IMM) ) is now available.
ImmuPharma PLC has announced an extension of warrants in Incanthera to 30 September 2025, allowing the company to potentially benefit from investment gains if Incanthera’s business development positively impacts its share price. This agreement, which includes a profit-sharing mechanism, is seen as advantageous for both companies and has been treated as a related party transaction due to the involvement of Tim McCarthy, who holds positions in both companies.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives, with a lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
YTD Price Performance: 145.00%
Average Trading Volume: 10,519,224
Technical Sentiment Signal: Hold
Current Market Cap: £14.69M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.